Orchestra BioMed Holdings (OBIO) Cash Flow: Operating & Free Cash Flow

Orchestra BioMed Holdings Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Orchestra BioMed Holdings, Inc. (OBIO) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Mar 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-52.70	-61.02	-61.02	-49.12	-33.61	-23.01	-21.36
Depreciation & Amortization	0.33	0.31	0.31	0.29	0.22	0.18	0.14
Deferred Income Tax	0.00	0.00	-	0.00	0.00	0.29	0.00
Stock Based Compensation	11.98	10.62	10.62	7.63	3.41	0.30	0.22
Change in Working Capital	-10.37	-0.77	-0.77	-3.31	-0.45	2.60	-8.12
Change in Accounts Receivable	0.00	0.02	0.02	0.00	0.03	0.05	-0.08
Change in Inventory	-0.14	-0.03	-0.03	0.13	-0.21	0.00	-0.03
Change in Accounts Payable	0.00	2.97	2.97	0.15	0.00	1.08	-2.61
Change in Other Working Capital	-10.23	-3.73	-1.72	-3.58	-0.27	1.47	-5.41
Other Operating Activities	1.81	0.31	0.31	-1.61	1.14	0.22	2.93
Net Cash from Operating Activities	-48.96	-50.56	-50.56	-46.13	-29.29	-19.43	-26.18
Investing Activities
Capital Expenditures	-0.49	-0.29	-0.29	-0.08	-0.59	-0.27	-0.54
Acquisitions	0.00	-0.60	-0.60	0.00	0.00	-13.29	-27.51
Purchases of Investments	-76.31	-72.65	86.63	-142.03	-63.53	-0.21	-15.62
Sales/Maturities of Investments	49.86	86.63	-72.65	152.80	0.00	13.50	43.13
Other Investing Activities	0.00	0.00	-	0.00	0.00	13.29	27.51
Net Cash from Investing Activities	-26.94	13.09	13.09	10.69	-64.12	13.02	26.97
Financing Activities
Debt Repayment	17.91	15.00	-	-10.85	3.55	-4.00	10.00
Common Stock Issued	71.97	15.04	15.28	0.25	109.83	0.01	162.29
Common Stock Repurchased	0.00	0.00	-0.55	0.00	0.00	0.00	0.00
Other Financing Activities	-1.55	-0.86	-0.55	56.81	-10.13	0.01	-162.29
Net Cash from Financing Activities	88.33	29.17	29.17	46.22	103.26	-3.99	10.00
Summary
Net Change in Cash	12.43	-8.30	-8.30	10.78	9.85	-10.41	10.78
Cash at Beginning of Period	22.26	30.56	30.56	19.78	9.94	20.34	9.56
Cash at End of Period	34.69	22.26	22.26	30.56	19.78	9.94	20.34
Free Cash Flow	-49.45	-50.85	-50.85	-46.21	-29.88	-19.70	-26.72
Supplemental Disclosures
Interest Paid	-	-	0.10	1.12	1.37	0.39	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Orchestra BioMed Holdings Cash Flow

What is Orchestra BioMed Holdings's free cash flow?

Orchestra BioMed Holdings had negative free cash flow of $49.45M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$48.96M minus $489.00K of capital expenditures.

How much does Orchestra BioMed Holdings spend on capital expenditures?

Orchestra BioMed Holdings spent $489.00K on capital expenditures in fiscal 2025, compared with $289.00K a year earlier.

Does Orchestra BioMed Holdings pay dividends or buy back shares?

Orchestra BioMed Holdings's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition